SHINE Technologies has raised $240M to expand its nuclear medicine operations, including large-scale production of Lutetium-177 used in targeted cancer therapies, following its recent acquisition of Lantheus’ SPECT business...
SHINE Technologies has completed the acquisition of the Lantheus SPECT portfolio and manufacturing facility while naming Michael Rossi as CEO of the new SHINE SPECT division...
Published by Nucleation Capital in Advanced Nuclear, Company Milestone, Fusion, Medical Isotopes, NEWS, Nuclear innovation, Nuclear R&D, Portfolio Venture, US competitiveness, Venture capital support for nuclear
SHINE is drawing renewed attention for its fusion-based isotope production as the US works to localize Mo-99 and reduce dependence on foreign reactors—an important shift for the nuclear medicine supply chain that underpins most diagnostic procedures...
Published by Nucleation Capital in Advanced Nuclear, Advanced Nuclear Customers, Fusion, Medical Isotopes, NEWS, Nuclear competitiveness, Nuclear innovation, Nuclear R&D, Portfolio Venture, Private companies, US competitiveness, US technological leadership
SHINE Technologies, a Nucleation portfolio venture and next-generation fusion company, today announced a strategic partnership with Sumitomo Corporation of Americas (SCOA), a leading global trading and investment company. The partnership, formalized through a Memorandum of Understanding (MOU), will explore and develop pathways for SCOA to promote and distribute SHINE's innovative products and services throughout Japan and other Asian markets.
Published by Nucleation Capital in Advanced Nuclear, Advanced Nuclear Customers, Fusion, International Collaboration, INTERNATIONAL NEWS, Medical Isotopes, Neutron services, NEWS, Nuclear waste, Portfolio Venture, Private companies
SHINE Technologies – A Wisconsin-based developer of fusion energy, commercializing in the interim their high flux neutrons from DT fusion for radiation effects testing, isotope production and waste separation enroute to development of cost-effective fusion energy, producing Ilumira, a potent cancer therapy, made from Lutetium-177.
Published by Nuclea_Admin in PORTFOLIO
Sign up to receive Nucleation Insights
For New Investors
For Donors & Advocates
For Current Investors
(Note: Must be logged in at AngelList)
Nucleation Direct Messages
Nucleation (Fund I) Posts
Your Portfolio Dashboard
Your Funding Page
How to Contact Us
© 2026 Nucleation Capital | Terms & Policies
